Master of Science

Provident Bancorp, Inc. Appoints Julienne Cassarino to Board of Directors

Retrieved on: 
Friday, February 16, 2024

AMESBURY, Mass., Feb. 16, 2024 /PRNewswire/ -- Provident Bancorp, Inc. (NASDAQ: PVBC), is pleased to announce the appointment of Julienne Cassarino to its Board of Directors, as well as the Board of Directors of its operating subsidiary, BankProv , a future-ready commercial bank that offers technology-driven banking solutions to its clients.

Key Points: 
  • AMESBURY, Mass., Feb. 16, 2024 /PRNewswire/ -- Provident Bancorp, Inc. (NASDAQ: PVBC), is pleased to announce the appointment of Julienne Cassarino to its Board of Directors, as well as the Board of Directors of its operating subsidiary, BankProv , a future-ready commercial bank that offers technology-driven banking solutions to its clients.
  • With over two decades of experience as a distinguished bank analyst and investor, Ms. Cassarino brings a wealth of knowledge and expertise to the board.
  • BankProv President and CEO, Joe Reilly, expressed his enthusiasm for Ms. Cassarino's appointment, stating, "We are thrilled to welcome Julienne to our Board of Directors.
  • Provident Bancorp, Inc. looks forward to benefiting from Ms. Cassarino's valuable contributions as she assumes her role on the Board of Directors.

Meatable Strengthens Board of Directors to Accelerate Growth of Breakthrough Food Technology

Retrieved on: 
Thursday, February 15, 2024

“Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.

Key Points: 
  • “Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.
  • On the Meatable Board, Mr. Abony will support the company’s management team by advising on commercial development initiatives in the U.S. as well as future transactions.
  • “Compared to others in its category, Meatable is highly differentiated through its industry-first technology and phased approach.
  • “Meatable is working at the forefront of food technology and is a clear-cut leader in the cultivated meat space,” said Ms. Malarkey.

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

“2024 CAPITAL LINK GREEK SHIPPING LEADERSHIP AWARD”

Retrieved on: 
Wednesday, February 14, 2024

Capital Link Greek Shipping Leadership Award, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "2024 Capital Link Greek Shipping Leadership Award" was presented to TEN LTD. -TSAKOS ENERGY NAVIGATION LTD., (NYSE: TNP) for reaching the milestone of 30 successful years as a public company, and to Dr. Nikolas P. Tsakos, Founder & CEO - TEN Ltd. (NYSE: TNP); Chairman INTERTANKO (2014-2018), for his outstanding contribution to Greek & global shipping.

Key Points: 
  • Capital Link Greek Shipping Leadership Award, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "2024 Capital Link Greek Shipping Leadership Award" was presented to TEN LTD. -TSAKOS ENERGY NAVIGATION LTD., (NYSE: TNP) for reaching the milestone of 30 successful years as a public company, and to Dr. Nikolas P. Tsakos, Founder & CEO - TEN Ltd. (NYSE: TNP); Chairman INTERTANKO (2014-2018), for his outstanding contribution to Greek & global shipping.
  • The Award Ceremony took place on Thursday, February 8, 2024, at the luncheon held in the context of the 14th Annual Capital Link Greek Shipping Forum.
  • With attendance exceeding 1,000, of which 750 attended the luncheon, the event featured the institutional and industry leadership of global and Greek shipping, and it has thus been rightly labeled as an unofficial Summit of Global Shipping.
  • The “Capital Link Greek Shipping Leadership Award” is presented annually to a leading maritime figure of the Greek Shipping Community who has gained the respect and the appreciation of the international shipping industry and who is also recognized for their outstanding contribution to elevating Greek Shipping to its leadership position globally.

New Initiative Launched to Accelerate the Use of AI in the Fight Against Neurodegenerative Diseases

Retrieved on: 
Tuesday, February 13, 2024

OAKLAND, Calif., Feb. 13, 2024 /PRNewswire/ -- The 10,000 Brains Project, an independent 501(c)(3) nonprofit organization, has been launched to promote the ethical use of artificial intelligence (AI) in the fight against Alzheimer's, Parkinson's, and other neurodegenerative diseases. The organization's mission is to provide the leadership, expertise, and financial support needed to ensure that researchers can rapidly adopt this powerful new technology in the search for better diagnostics and treatments for patients in need.

Key Points: 
  • Neurodegeneration is perhaps the most complex challenge in healthcare and the development of treatments has proven resistant to traditional research methods.
  • Patrick Brannelly, a seasoned executive in nonprofit and entrepreneurial ventures, has been named the founding CEO of The 10,000 Brains Project.
  • We are excited to build a research roadmap that will show how private funding can accelerate this important area of medical research."
  • First, solving neurodegenerative diseases will require researchers to recognize the full diversity of human brains; every person's brain is different, and their disorders can take a variety of different paths.

Children’s Hospital Los Angeles Unveils New Fetal Cardiac Clinic

Retrieved on: 
Tuesday, February 13, 2024

Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.

Key Points: 
  • Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240213588362/en/
    The Heart Institute at Children's Hospital Los Angeles celebrates the opening of its new Fetal Cardiac Clinic.
  • “With the launch of our new Fetal Cardiac Clinic, we now have a dedicated space that can serve as a one-stop shop for families in need of comprehensive prenatal diagnostic testing and counseling for cardiac anomalies.”
    CHLA’s state-of-the-art Fetal Cardiac Clinic features over 3,000 square feet of space and three scanning rooms dedicated to fetal cardiology.
  • Services provided at the CHLA Fetal Cardiac Clinic include:
    To learn more about CHLA’s Fetal Cardiac Clinic, visit CHLA.org/FetalCardiology or call 323-361-7398.

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Retrieved on: 
Tuesday, February 13, 2024

JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.

Key Points: 
  • JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.
  • Scinai's broad pharmaceutical development experience, along with its end-to-end biologics drug development and GMP manufacturing facility, drove the Q3 2023 launch of Scinai Bioservices, a boutique end-to-end CDMO business unit, to assist biotech companies efficiently bring their products to market.
  • In addition to expanding the CDMO's business development and sales activities, Halpert will support partnering and out-licensing activities with mid and large cap pharma companies with which Scinai plans on bringing the NanoAbs through clinical trials and towards commercialization.
  • Halpert commented, "I am thrilled to join Scinai where I'll be leading business development and sales of our state-of-the-art end-to-end CDMO services in the global biotech arena.

Vianode appoints Howard Ormonroyd as CFO, bringing extensive experience in financing large-scale materials and infrastructure projects

Retrieved on: 
Tuesday, February 13, 2024

OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has appointed Howard Ormonroyd as CFO.

Key Points: 
  • OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has appointed Howard Ormonroyd as CFO.
  • "Howard adds a unique combination of financial expertise and extensive experience from the energy, industrial and renewables markets, together with global managerial competence.
  • Ormonroyd has a proven track record of facilitating large and attractive financing for rapidly growing companies.
  • Vianode is positioning to meet increasing demand for batteries and anode graphite solutions driven by global electrification and EV deployment.

Vianode appoints Howard Ormonroyd as CFO, bringing extensive experience in financing large-scale materials and infrastructure projects

Retrieved on: 
Tuesday, February 13, 2024

OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has appointed Howard Ormonroyd as CFO.

Key Points: 
  • OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has appointed Howard Ormonroyd as CFO.
  • "Howard adds a unique combination of financial expertise and extensive experience from the energy, industrial and renewables markets, together with global managerial competence.
  • Ormonroyd has a proven track record of facilitating large and attractive financing for rapidly growing companies.
  • Vianode is positioning to meet increasing demand for batteries and anode graphite solutions driven by global electrification and EV deployment.